

QIBA CT Volumetry Technical Committee Update Call

January 9, 2012 at 11 AM CST

DRAFT Call Summary

In attendance:

P. David Mozley, MD (Co-chair)

Lawrence Schwartz, MD (Co-chair)

Maria Athellogou, PhD

Hubert Beaumont, PhD

Andrew Buckler, MS

Paul L. Carson, PhD

Baiyu Chen, PhD

David A. Clunie, MBBS

Barbara Croft, MD

Paul R. Garrett, MD

Gregory V. Goldmacher, MD, PhD

Luna Hilaire, PhD

Philip F. Judy, PhD

James Mulshine, MD

Kevin O'Donnell, MASc

Nicholas Petrick, PhD

Michael Rosenthal, MD, PhD

Neil Steinmetz, MD, JD

Daniel C. Sullivan, MD

Ying Tang, PhD

Binsheng Zhao, DSc

RSNA:

Joe Koudelik

Madeleine McCoy

Continued NIBIB funding beyond current contract possible

- A new proposal for continued NIBIB funding was discussed due to no possibility of an extension or renewal of the current contract (ending September 2012). The new proposal should be well thought out and in accordance with the NIBIB funding mission (eg, determining outcomes for biomarkers not in the NIBIB mission).
- Pursuing additional biomarkers vs. incorporating additional biomarker features (ie, content of use) requires more discussion
- The scope of QIBA was discussed with the following conclusions:
 - The RSNA is not a clinical trial organization; determining technical performance (accuracy) of metrics, response criteria and biomarker qualification for clinical utility deemed an appropriate scope

QIBA Vol-CT AdvDisease v2 Public Comment Profile Feedback (led by Mr. O'Donnell)

- Update: Mr. O'Donnell color-coded the comment resolution document and suggested homework assignments
- The goal is to have the Tech Ctte look over the completed homework/comments and confirm as resolved
 - Yellow: Assigned homework
 - White: Unassigned homework
 - Green: Completed homework; for Tech Ctte discussion/resolution
 - Gray: Finalized text
- Wordsmithing changes included:
 - Line 72 #64: Changing "Physician Pls of Clinical Trials" to "Clinical Trialists" to encompass a broader audience
 - Line 80 #65: "Tumors" were changed to "Lesions" throughout the Profile with the exception of two references
 - Detection and classification of lesions as target and/or evaluable is beyond the scope of this document
 - Line 248 #161: Dr. Steinmetz to propose some requirement language on the Interpreting Physician (e.g. selection of the target lesions, validation of the measurement results, selection of protocol and contrast, etc)
 - Profile line 148 lesion language was changed to images of a lesion; grammatically correct
 - Table summarizing precision/reproducibility of volumetric measurements from clinical studies reported in the literature: group to look over the mathematical equations before the next t-con.
- Mr. O'Donnell to verify that Table 1 is updated: Actors and Required Activities

Next steps:

- Mr. O'Donnell to post the updated versions of the profile and comment resolution document to the WIKI
- Discussion of the comment/resolution editorial process (ie, is the process working?)
- Next call scheduled for Monday, January 16th at 11 am CST